** = Publications listed in SCI/SSCI/Pubmed
** Schwegel, N; Toferer, C; Zach, DK; Santner, V; Höller, V; Lugitsch, J; Wallner, M; Gollmer, J; Aziz, F; von, Lewinski, D; Kolesnik, E; Ablasser, K; Zirlik, A; Sourij, H; Verheyen, N
Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study.
J Clin Med. 2024; 13(19):
Doi: 10.3390/jcm13195966
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Lugitsch, J; Hoeller, V; Schwegel, N; Santner, V; Gollmer, J; Kolesnik, E; Lipp, R; Niedrist, T; Rainer, P; Zirlik, A; Ablasser, K; Verheyen, N; Zach, D
Interleukin-6 plasma levels predict mortality and heart failure events in cardiac transthyretin amyloidosis
EUR HEART J. 2023; 44: -Annual Meeting of the European-Society-of-Cardiology (ESC); AUG 25-28, 2023; Amsterdam, NETHERLANDS.
[Poster]
Web of Science
** Lugitsch, J; Holler, V; Schwegel, N; Santner, V; Gollmer, J; Kolesnik, E; Lipp, R; Niedrist, T; Rainer, P; Zirlik, A; Ablasser, K; Verheyen, N; Zach, D
Interleukin-6 plasma levels predict mortality and heart failure events in cardiac transthyretin amyloidosis
WIEN KLIN WOCHENSCHR. 2023; 135: S472-S473.
[Poster]
Web of Science
FullText